• Revenue growth guidance: After registering 18% top-line and bottom-line growth in Q4, UPL has guided for 10% to 14% revenue growth in Q1, reflecting historical seasonality where Q1 is typically a slower, flat quarter.
• Capex and expansion: Capex is expected to increase to $300–$350 million, with 40% to 45% allocated to intangible R&D and the remainder funding backward integration and capacity expansion in specialty chemicals.
• Deleveraging progress: Absolute net debt was reduced by 48% from $3.1 billion in 2024 to $1.6 billion, bringing the net debt-to-EBITDA ratio down from 4.2 times to below 1.6 times, near the mid-term target of under 1.5 times.
• Export operations: Under the Superform manufacturing platform—which is 72% AgChem—major output supplies the global crop protection business, while 40% to 50% of specialty chemical volumes are exported.